Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology makes the Voyager platform, a system of instruments, consumables and software for measuring proteins in research. It last closed at $2.36 on Nov 17, up 12.38% on the day. The average 12-month price target from 2 analysts is $3.75 (+58.9% from the last close), with a high of $4.00 and a low of $3.50. In the past 30 days there were 1 dark pool print totaling $149K, the largest $149K.
Key Stats
Last 12 monthsNot reported for this period.
From NAUT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 27). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on NAUT in the past 90 days. The average target is $3.75, with a high of $4.00 and a low of $3.50, compared with the last close of $2.36.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 29 | Roth Capital | Initiated | Buy | $3.50 |
| Sep 9 | Leerink Partners | Initiated | Buy | $4 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 10% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 52). The nearest support is the Pivot at $2.31, and the nearest resistance the swing high (Jun 25) at $2.45.
| RSI (14) | 51.62 | Middle of its range | Neutral |
| MACD | 0.06 | Below its signal line | Bearish |
| Stochastic | 18.9 | Near the bottom of its range | Oversold |
| ADX (14) | 25.4 | Trending up | |
| Williams %R | -74.1 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -52.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +0.4% | Change over 10 sessions | Bullish |
| ATR (14) | $0.33 | Typical daily range, 13.8% of price |
| RSI (14) | 55.66 | Middle of its range | Neutral |
| MACD | 0.14 | Above its signal line | Bullish |
| Stochastic | 56.7 | Middle of its range | Neutral |
| ADX (14) | 36.2 | Trending up | |
| Williams %R | -41.2 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 77.0 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +131.4% | Change over 10 sessions | Bullish |
| ATR (14) | $0.52 | Typical daily range, 21.9% of price |
What happened before
See how NAUT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NAUT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in NAUT in the last 90 days.
Dark Pool
30DNAUT Institutional Ownership
Full report →- ▲45 buying vs 35 selling
- ▼Held by funds -5.6 pts
- ▼Funds holding -6
- ▼Superinvestors: 1 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 87 | 93 | −6.5% |
| In funds' top 10 | 0 | 1 | −100.0% |
| Held by funds | 33.8% | 39.4% | −5.6 pts |
| New / increased | 10 / 35 | 30 / 29 | −23.7% |
| Reduced / sold out | 19 / 16 | 11 / 17 | +25.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NAUT is in one of them and how their past NAUT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NAUT in an article yet. Here's the latest on the wider market.
About Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company based in Seattle, Washington, that is developing tools for measuring proteins in biological samples. Its Voyager platform combines instruments, consumables and software for proteomics research, with the aim of counting protein and protein variant levels one molecule at a time. The company serves researchers and life science customers. For now it offers analysis services to a limited group of early access customers while it works toward broader commercial sales. Its technology is aimed at drug discovery, biomarker research and precision medicine.
- Headquarters
- Seattle, WA



